Adeno-Associated Virus (AAV) Versus Immune Response

• Main Authors: Joseph Rabinowitz, Ying Kai Chan, Richard Jude Samulski
• Format: Article
• Language: English
• Published: MDPI AG 2019-01-01
• Series: Viruses
• Subjects: rAAV; immune response; rare diseases
• Online Access: https://www.mdpi.com/1999-4915/11/2/102

Decades ago, Friedmann and Roblin postulated several barriers to gene therapy, including tissue targeting, delivery across the blood⁻brain barrier (BBB), and host immune responses. These issues remain pertinent till today. Since then, several advances have been made in elucidating structures of adeno-associated virus (AAV) serotypes, antibody epitopes, and ways to modify antibody-binding sites. AAVs capsid has also been engineered to re-direct tissue tropism, reduce ubiquitination, and promote passage across the BBB. Furthermore, the use of high(er) dose recombinant AAV (rAAV) has been accompanied by a better understanding of immune responses in both experimental animals and early clinical trials, and novel work is being performed to modulate the immune response. While the immune responses to rAAV remains a major challenge in translating experimental drugs to approved medicine, and will likely require more than a single solution, we now better understand the hurdles to formulate and test experimental solutions to surmount them.